SEC For	m 4																		
	FORM	4	UNITE	D STA	TES	s se	ECU					NGE	СОМ	MIS	SSION				1
		Washington, D.C. 20549												OMB APPROVAL			VAL		
Section obligat	this box if no l n 16. Form 4 o ions may conti tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934									RS	Estimated average burden				3235-0287 en 0.5			
	T III	or	Section	on 30	(h) of the	Investme	ent Co	mpany Act	of 1940	1334									
1. Name and Address of Reporting Person [*] <u>KEATING LAURIE</u>					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol <u>ALNYLAM PHARMACEUTICALS, INC.</u> [ALNY]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Cofficer (give title Other (specif				wner
	(F ST KEND A. TERME	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 04/20/2020									EVP, Chief Legal Officer					
					. 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applica Line)				oplicable
(Street) CAMBRIDGE MA 02142			02142										ne Reporting Person lore than One Reporting						
(City)	(5	State)	(Zip)																
		Tab	ole I - No	n-Deriv	/ativ	e Se	curit	ties Ac	quired	, Dis	posed o	f, or B	enefic	ially	y Owned				
1. Title of Security (Instr. 3) Date (Month/E					ar) if	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code) 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)					Form ly (D) o		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	r Pric	e	Transactio	on(s) nd 4)			(instr. 4)
Common Stock 04/20				/2020)					10,000) A	\$7	77.4	24,4	192		D		
Common Stock 04/2				04/20	/2020						10,000) D	\$	139	14,492			D	
Common Stock													434		4	I		by Managed Account ⁽²⁾	
		-	Table II -								osed of, convertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemo Execution if any (Month/Da	ed Date,	4. Transa	ransaction		5. Number of		6. Date Exercis Expiration Date (Month/Day/Yea		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ount	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$77.4	04/20/2020	1		M ⁽¹⁾			10,000	,000 (3) 09/22/202		09/22/2024	Commor Stock	¹ 10,0	000	\$0.0 42,00		00	D	

Explanation of Responses:

1. All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

2. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

3. The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

<u>By: /s/ Mary Beth DeLena,</u> <u>Attorney-in-Fact For: Laurie</u>

Keating

e <u>04/22/2020</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.